Zim Laboratories Limited

Zim Laboratories Limited

Zim Laboratories Limited has received a Certificate of Good Manufacturing Practice (GMP) Compliance from Australia's Therapeutic Goods Administration (TGA) for its manufacturing facility at B-21/22, MIDC Area, Kalmeshwar, Nagpur, Maharashtra. The certification covers the manufacture of non-sterile finished products across both registered and listed therapeutic goods categories.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange that CARE Ratings Limited has reaffirmed the ratings with a revised outlook on the company's bank facilities.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance under Regulation 74(5) for the quarter ended on 30th September, 2026.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window for dealing with securities of the Company will remain closed from Thursday, the 01st October, 2026, for Designated Persons and their immediate relatives.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange about the incorporation of a wholly owned subsidiary in Chile, ZIM Laboratories SpA, with 100% shareholding and cash consideration.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange about General Updates regarding the completion of investment in ZIM Scientific Office LLC Step-down Subsidiary by ZIM Laboratories Limited FZE, a wholly owned subsidiary.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange about the transcript of Q1 FY27 Earnings Conference Call, where the management discussed the company's financial results, EU-GMP remediation process, and business outlook.

Zim Laboratories Limited

Zim Laboratories Limited has submitted the Exchange a copy Scrutinizer report of Postal Ballot. The company has informed the Exchange regarding voting results. The Special Resolutions as proposed in the notice of the Postal Ballot were passed by the Members with requisite majority.

Zim Laboratories Limited

Zim Laboratories Limited has made the audio recording of its Q1 FY27 earnings conference call available on its website.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange about the publication of financial results for the quarter ended 30.06.2026, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange about Earnings Presentation - Q1 FY27, with Q1 FY27 financial highlights showing a 31.2% increase in total operating income and a 40.0% decrease in EBITDA.

Zim Laboratories Limited

Zim Laboratories Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, which includes revenue from operations of Rs. 9,417.85 lakhs and total income of Rs. 9,517.08 lakhs. The company's expenses include cost of materials consumed of Rs. 4,381.61 lakhs and total expenses of Rs. 5,432.52 lakhs. The results are subject to a limited review by Deloitte Haskins & Sells LLP.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange about the schedule of a Q1FY27 Earnings Conference Call to be held on Friday, 07th August, 2026 at 12:00 p.m. IST. The call will be hosted by Go India Advisors and will feature company participants Mr. Zulfiquar Kamal, Mr. Shyam Mohan Patro, and Mr. Zain Daud.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange about the transfer of equity shares to Investor Education and Protection Fund (IEPF) Account, as per the requirements of Section 124(6) of the Companies Act, 2013, and Rule 6(3) of the Investor Education and Protection Fund (IEPF) Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange regarding allotment of 109451 securities pursuant to ESOP/ESPS at its meeting held on July 13, 2026, increasing the paid-up equity share capital from Rs. 53,54,90,370 to Rs. 53,65,84,880.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance under Regulation 74(5) for the quarter ended on 30th June, 2026.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange regarding Notice of Postal Ballot for seeking approval of the Members of the Company on the Special Resolution forming part of the Notice.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange about the schedule of an Investors / Analysts Meet, to be held on July 3, 2026, with Canara HSBC Life Insurance. The meeting is subject to change due to exigencies, and no unpublished price sensitive information will be shared.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange about the schedule of an Investors / Analysts Meet on July 3rd, 2026, with Tata Asset Management Pvt. Ltd.

Zim Laboratories Limited

Zim Laboratories Limited has informed the Exchange regarding voting results of Annual General Meeting held on Jun 29, 2026.